These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 27834194)

  • 1. Risk of Bleeding in Patients on Full-Dose Enoxaparin With Venous Thromboembolism and Selective Serotonin Reuptake Inhibitors.
    Samuel NG; Seifert CF
    Ann Pharmacother; 2017 Mar; 51(3):226-231. PubMed ID: 27834194
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
    Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
    JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety and efficacy of use of low-molecular-weight heparin in pediatric neurosurgical patients.
    Gonda DD; Fridley J; Ryan SL; Briceño V; Lam SK; Luerssen TG; Jea A
    J Neurosurg Pediatr; 2015 Sep; 16(3):329-34. PubMed ID: 26067336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
    Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R;
    Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recurrence of malignancy-associated venous thromboembolism among patients treated with rivaroxaban compared to enoxaparin.
    Nicklaus MD; Ludwig SL; Kettle JK
    J Oncol Pharm Pract; 2018 Apr; 24(3):185-189. PubMed ID: 29284351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective Evaluation of Postoperative Adverse Drug Events in Patients Receiving Rivaroxaban After Major Orthopedic Surgery Compared with Standard Therapy in a Community Hospital.
    Cieri NE; Kusmierski K; Lackie C; Van Opdorp A; Hassan AK
    Pharmacotherapy; 2017 Feb; 37(2):170-176. PubMed ID: 28028830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of High-Dose Unfractionated Heparin Versus High-Dose Enoxaparin for Venous Thromboembolism Prevention in Morbidly Obese Hospitalized Patients.
    Mason SW; Barber A; Jones E; Chen SL; Moll S; Northam K
    Am J Med; 2020 Jun; 133(6):e249-e259. PubMed ID: 31862336
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Direct Oral Anticoagulants Vs. Enoxaparin for Prevention of Venous Thromboembolism Following Orthopedic Surgery: A Dose-Response Meta-analysis.
    Boyd RA; DiCarlo L; Mandema JW
    Clin Transl Sci; 2017 Jul; 10(4):260-270. PubMed ID: 28467656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer.
    Lee JH; Oh YM; Lee SD; Lee JS
    J Korean Med Sci; 2019 Jun; 34(21):e160. PubMed ID: 31144482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. No difference in bleeding risk between subcutaneous enoxaparin and heparin for thromboprophylaxis in end-stage renal disease.
    Chan KE; Thadhani RI; Maddux FW
    Kidney Int; 2013 Sep; 84(3):555-61. PubMed ID: 23677243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
    Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
    Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased Enoxaparin Dosing for Venous Thromboembolism Prophylaxis in General Trauma Patients.
    Walker CK; Sandmann EA; Horyna TJ; Gales MA
    Ann Pharmacother; 2017 Apr; 51(4):323-331. PubMed ID: 28228055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiative to improve thromboprophylactic enoxaparin exposure in hospitalized patients with renal impairment.
    Elsaid KA; Collins CM
    Am J Health Syst Pharm; 2012 Mar; 69(5):390-6. PubMed ID: 22345418
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboprophylaxis with enoxaparin and direct oral anticoagulants in major orthopedic surgery and acutely ill medical patients: a meta-analysis.
    Cimminiello C; Prandoni P; Agnelli G; Di Minno G; Polo Friz H; Scaglione F; Boracchi P; Marano G; Harenberg J
    Intern Emerg Med; 2017 Dec; 12(8):1291-1305. PubMed ID: 28756546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of venous thromboembolism with new oral anticoagulants versus standard pharmacological treatment in acute medically ill patients: a systematic review and meta-analysis.
    Albertsen IE; Larsen TB; Rasmussen LH; Overvad TF; Lip GY
    Drugs; 2012 Sep; 72(13):1755-64. PubMed ID: 22876779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials.
    van Doormaal FF; Raskob GE; Davidson BL; Decousus H; Gallus A; Lensing AW; Piovella F; Prins MH; Büller HR
    Thromb Haemost; 2009 Apr; 101(4):762-9. PubMed ID: 19350123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.
    Prandoni P; Prins MH; Cohen AT; Müller K; Pap ÁF; Tewes MC; Lensing AW
    Acad Emerg Med; 2015 Feb; 22(2):142-9. PubMed ID: 25676529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.
    Agnelli G; Buller HR; Cohen A; Gallus AS; Lee TC; Pak R; Raskob GE; Weitz JI; Yamabe T
    J Thromb Haemost; 2015 Dec; 13(12):2187-91. PubMed ID: 26407753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
    Signorelli JR; Gandhi AS
    J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivaroxaban for thromboprophylaxis among patients recently hospitalized for acute infectious diseases: a subgroup analysis of the MAGELLAN study.
    Cohoon KP; De Sanctis Y; Haskell L; McBane RD; Spiro TE
    J Thromb Haemost; 2018 Jul; 16(7):1278-1287. PubMed ID: 29753308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.